What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.”In the company’s words, NCT07039578 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (MM) (2 trials), Primary Light-Chain Amyloidosis, Multiple Myeloma, Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome, Primary Sjögren's Syndrome (pSS)
- Main trialPhase 3
- “The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.”In the company’s words, NCT07181239 on ClinicalTrials.gov
Other drugs for Multiple Myeloma (MM)
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
- DaratumumabJanssen Research & Development, LLC · Phase 3
Coming up5
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 18 Nov 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Apr 2028Phase 1 trial completes · ClinicalTrials.gov
- May 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Sep 2027 | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | |
| Phase 3Not yet recruiting | May 2030 | Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Recruiting | 30 Jun 2026 | Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis | |
| Phase 1/2Recruiting | Dec 2026 | A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | |
| Phase 1/2Recruiting | 18 Nov 2027 | A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia | |
| Phase 1Not yet recruiting | Apr 2028 | CM336 for Active Sjogren's Syndrome Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026